Pluri Inc. (PLUR) stock
PLURNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
$1.05−0.04 (-3.67%)
Close on Nov 13, 2026Market cap $12.96MP/E –Yield –
Pluri r&d expenses
Research and development expenses are spending on new products and technology.
Pluri's R&D Expenses for the twelve months ending Sep 30, 2026 was $24.83M, up 78.7% year over year. For fiscal 2026 it was $15.09M, up 17.4% from the year before. Over ten years it grew -4.1% a year on average. The highest annual figure on record is $30.53M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $15.09M | +17.4% |
| FY2025 | Jun 30, 2025 | $12.85M | +3.3% |
| FY2024 | Jun 30, 2024 | $12.45M | -21.0% |
| FY2023 | Jun 30, 2023 | $15.75M | -36.0% |
| FY2022 | Jun 30, 2022 | $24.61M | -19.4% |
| FY2021 | Jun 30, 2021 | $30.53M | +32.2% |
| FY2020 | Jun 30, 2020 | $23.10M | -22.7% |
| FY2019 | Jun 30, 2019 | $29.88M | +13.3% |
| FY2018 | Jun 30, 2018 | $26.37M | +9.9% |
| FY2017 | Jun 30, 2017 | $24.00M | +5.0% |
| FY2016 | Jun 30, 2016 | $22.86M | -2.4% |
| FY2015 | Jun 30, 2015 | $23.42M | -6.1% |
| FY2014 | Jun 30, 2014 | $24.94M | +25.3% |
| FY2013 | Jun 30, 2013 | $19.91M | +56.9% |
| FY2012 | Jun 30, 2012 | $12.69M | +52.6% |
| FY2011 | Jun 30, 2011 | $8.31M | +35.7% |
| FY2010 | Jun 30, 2010 | $6.12M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $13.67M | +247.7% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $3.37M | -15.5% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $3.96M | +30.2% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $3.83M | +30.8% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $3.93M | +36.1% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $3.99M | +17.6% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $3.04M | -1.6% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $2.93M | -1.3% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $2.89M | -3.5% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $3.40M | -3.6% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $3.09M | -25.7% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $2.96M | -21.7% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $2.99M | -33.5% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $3.52M | -34.8% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $4.17M | -33.6% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $3.79M | -42.1% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $4.50M | -29.5% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $5.40M | -36.5% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $6.27M | -19.8% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $6.54M | -18.2% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $6.39M | +3.0% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $8.51M | +42.8% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $7.82M | +36.3% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $8.00M | +43.6% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $6.20M | +6.5% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $5.96M | -4.9% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $5.74M | -31.8% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $5.57M | -25.0% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $5.83M | -25.0% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $6.26M | -15.8% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $8.42M | +12.6% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $7.43M | +18.7% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $7.77M | +49.6% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $7.44M | +25.9% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $7.48M | +13.7% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $6.26M | +14.2% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $5.19M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $5.91M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $6.58M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $5.48M | – |
See a number that looks wrong?